World GI: CONCUR Study Shows Improvement in Survival Outcomes with Regorafenib

The results of this double blind, placebo controlled trial show that patients with stage IV adenocarcinoma of the colon or rectum have increased overall survival when treated with regorafenib. The median OS in the regorafenib group was 8.8 months compared to 6.3 months with placebo (Hazard Ratio (HR) = 0.550, p=0.0002). Secondary endpoints showed similar results with an increase in PFS for patients receiving regorafenib 3.2 months compared to 1.7 months, (HR= 0.311, p=<0.0001); and disease control rate (DCR) 52% vs 7%, respectively. Click here to read more.